Massive Bio

Massive Bio is a New York-based digital health company founded in 2015 that leverages artificial intelligence to match cancer patients with suitable clinical trials. Its platform analyzes over 500 medical data elements to connect patients, physicians, and pharmaceutical sponsors, addressing a critical bottleneck in oncology research and patient care. The company operates a services-based business model, generating revenue by facilitating patient enrollment for trial sponsors while providing a free service to patients. It has onboarded over 190,000 patients and tracks more than 19,000 active oncology and hematology trials globally.

AI-powered platform that aggregates and analyzes patient medical data (500+ elements) against a global database of oncology clinical trials to identify matches. Combines machine learning algorithms with human clinical expertise for patient onboarding, matching, and enrollment support.

Massive Bio competes in the clinical trial patient recruitment and matching space. Direct competitors include other AI-driven startups like Antidote Technologies and Deep 6 AI. It also faces competition from large Contract Research Organizations (CROs) that offer patient recruitment services and from electronic health record (EHR) companies integrating trial matching tools. Its differentiation lies in its specific focus on oncology, its global trial database, and its hybrid AI-plus-human concierge model.